$PBIO Financial Results: Q2 2019 vs. Q2 2018 (roun
Post# of 25438
(Total Views: 330)
Posted On: 08/15/2019 3:01:02 PM
$PBIO Financial Results: Q2 2019 vs. Q2 2018 (rounded to nearest hundred except for EPS)
Total revenue for the second quarter ended June 30, 2019 was $518,700 compared to $638,800 for the same period in 2018, a 19% decrease. Product and services revenue was $518,700 for the second quarter of 2019 compared to $618,400 for the same quarter of 2018, a 16% decrease. Instrument sales decreased to $247,000 in Q2 2019 compared to $397,000 in Q2 2018, a decrease of 38%. Sales of consumables were $91,400 for the second quarter of 2019 (an all-time record) compared to $64,100 for the same period in 2018, a 43% increase. BaroFold contract services for protein disaggregation and controlled refolding applications were $69,700 for the 2019 second quarter compared to $52,600 for the same period in 2018, an increase of 32.5%. UST contract services reached $41,400 in Q2 2019 compared to $14,300 in the second quarter of 2018, an increase of 197.5%. Grant revenue in Q2 2019 was none compared to $20,000 in Q2 2018. Our NIH grant ended in November 2018.
Operating loss for Q2 2019 was $1,400,400 compared to $920,900 for the same period in 2018. This increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.
Loss per common share - basic and diluted- was $(2.22) for Q2 2019 compared to loss per common share of $(9.20) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.
Financial Results: First Half (1H) 2019 vs. First Half (1H) 2018 (rounded to nearest hundred except for EPS)
Total revenue for the 1H 2019 was $1,028,900 compared to $1,249,500 for the prior year same period, a decrease of $220,600 or 18%. This decrease was primarily due to lower revenue from instrument sales, as described below. We believe total revenue will increase over the remaining two quarters of 2019. Product and services revenue decreased to $1,028,900 for the first half of 2019 compared to $1,203,700 for the same period in 2018, a decrease of $174,800 or 15%. Comparing 1H 2019 to 1H 2018, instrument sales decreased to $385,700 from $817,100, consumable sales increased to $153,400 (an all-time record) from $138,800, BaroFold contract services increased to $220,800 from $52,600, and UST contract services reached $128,300 compared to $14,300. We believe product and services revenue will continue to increase (YoY) for the remaining quarters of 2019.
Operating loss was $2,797,000 for the first six months of 2019, compared to a loss of $2,029,000 for the same period in 2018, an increase of $768,000 or 38%. The increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.
Net loss per common share was $(4.24) -- basic and diluted -- for the six months ended June 30, 2019 compared to a net loss per common share -- basic and diluted -- of $(11.01) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.
https://www.bloomberg.com/press-releases/2019...ess-update
Total revenue for the second quarter ended June 30, 2019 was $518,700 compared to $638,800 for the same period in 2018, a 19% decrease. Product and services revenue was $518,700 for the second quarter of 2019 compared to $618,400 for the same quarter of 2018, a 16% decrease. Instrument sales decreased to $247,000 in Q2 2019 compared to $397,000 in Q2 2018, a decrease of 38%. Sales of consumables were $91,400 for the second quarter of 2019 (an all-time record) compared to $64,100 for the same period in 2018, a 43% increase. BaroFold contract services for protein disaggregation and controlled refolding applications were $69,700 for the 2019 second quarter compared to $52,600 for the same period in 2018, an increase of 32.5%. UST contract services reached $41,400 in Q2 2019 compared to $14,300 in the second quarter of 2018, an increase of 197.5%. Grant revenue in Q2 2019 was none compared to $20,000 in Q2 2018. Our NIH grant ended in November 2018.
Operating loss for Q2 2019 was $1,400,400 compared to $920,900 for the same period in 2018. This increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.
Loss per common share - basic and diluted- was $(2.22) for Q2 2019 compared to loss per common share of $(9.20) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.
Financial Results: First Half (1H) 2019 vs. First Half (1H) 2018 (rounded to nearest hundred except for EPS)
Total revenue for the 1H 2019 was $1,028,900 compared to $1,249,500 for the prior year same period, a decrease of $220,600 or 18%. This decrease was primarily due to lower revenue from instrument sales, as described below. We believe total revenue will increase over the remaining two quarters of 2019. Product and services revenue decreased to $1,028,900 for the first half of 2019 compared to $1,203,700 for the same period in 2018, a decrease of $174,800 or 15%. Comparing 1H 2019 to 1H 2018, instrument sales decreased to $385,700 from $817,100, consumable sales increased to $153,400 (an all-time record) from $138,800, BaroFold contract services increased to $220,800 from $52,600, and UST contract services reached $128,300 compared to $14,300. We believe product and services revenue will continue to increase (YoY) for the remaining quarters of 2019.
Operating loss was $2,797,000 for the first six months of 2019, compared to a loss of $2,029,000 for the same period in 2018, an increase of $768,000 or 38%. The increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.
Net loss per common share was $(4.24) -- basic and diluted -- for the six months ended June 30, 2019 compared to a net loss per common share -- basic and diluted -- of $(11.01) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.
https://www.bloomberg.com/press-releases/2019...ess-update
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!